News >

Radium-223/Abiraterone Phase III mCRPC Trial Unblinded

Jason M. Broderick @jasoncology
Published: Friday, Dec 01, 2017

Prostate Cancer
The phase III ERA223 trial exploring radium-223 dichloride (Xofigo) plus abiraterone acetate (Zytiga) in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) has been unblinded early.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication